Recent advances in leprosy and Buruli ulcer (Mycobacterium ulcerans infection)

Current Opinion in Infectious Diseases

Volumn 23, Issue 5, 2010, Pages 445-455

  Walsh, Douglas S ^a   Portaels, Françoise ^b   Meyers, Wayne M ^c  

^a U S ARMY   (United States)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

Buruli ulcer; leprosy; Mycobacterium leprae; Mycobacterium ulcerans

Indexed keywords

BCG VACCINE; CLARITHROMYCIN; CLOFAZIMINE; CORTICOSTEROID; DAPSONE; MACROLIDE; MINOCYCLINE; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; THALIDOMIDE;

BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BURULI ULCER; COMBINATION CHEMOTHERAPY; GENETIC POLYMORPHISM; HUMAN; IMMUNOGENICITY; INFECTION SENSITIVITY; INNATE IMMUNITY; LEPROSY; MOLECULAR EPIDEMIOLOGY; MYCOBACTERIUM; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM LEPROMATOSIS; PATHOGENICITY; RELAPSE; REVIEW;

ANTI-BACTERIAL AGENTS; BURULI ULCER; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEPROSY; MOLECULAR EPIDEMIOLOGY; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM ULCERANS; VIRULENCE;

EID: 77956228054     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32833c2209     Document Type: Review

References (147)

1. Han XY, Seo YH, Sizer KC, et al. A new Mycobacterium species causing diffuse lepromatous leprosy. Am J Clin Pathol 2008; 130:856-864.
2. Han XY, Sizer KC, Thompson EJ, et al. Comparative sequence analysis of Mycobacterium leprae and the new leprosy-causing Mycobacterium lepromatosis. J Bacteriol 2009; 191:6067-6074.
3. Parkash O. Classification of leprosy into multibacillary and paucibacillary groups: an analysis. FEMS Immunol Med Microbiol 2009; 55:1-5.
4. Akama T, Suzuki K, Tanigawa K, et al. Whole-genome tiling array analysis of Mycobacterium leprae RNA reveals high expression of pseudogenes and noncoding regions. J Bacteriol 2009; 191:3321-3327.
5. Cole ST, Eiglmeier K, Parkhill J, et al. Massive gene decay in the leprosy bacillus. Nature 2001; 409:1007-1011.
6. Maiden MC. Putting leprosy on the map. Nat Genet 2009; 41:1264-1266.
7. Monot M, Honore N, Garnier T, et al. On the origin of leprosy. Science 2005; 308:1040-1042.
8. Monot M, Honore N, Garnier T, et al. Comparative genomic and phylogeographic analysis of Mycobacterium leprae. Nat Genet 2009; 41:1282-1289.
9. RobbinsG, Tripathy VM, MisraVN, etal. Ancient skeletal evidence for leprosy in India (2000 B.C.). PLoS One 2009; 4:e5669.
10. Matheson CD, Vernon KK, Lahti A, et al. Molecular exploration of the first-century Tomb of the Shroud in Akeldama, Jerusalem. PLoS One 2009;4:e8319.
11. Kimura M, Sakamuri RM, Groathouse NA, et al. Rapid variable-number tandem-repeat genotyping for Mycobacterium leprae clinical specimens. J Clin Microbiol 2009; 47:1757-1766.
12. Sakamuri RM, Harrison J, Gelber R, et al. A continuation: study and characterisation of Mycobacterium leprae short tandem repeat genotypes and transmission of leprosy in Cebu, Philippines. Lepr Rev 2009; 80:272-279.
13. Watson CL, Lockwood DN. Single nucleotide polymorphism analysis of European archaeological M. leprae DNA. PLoS One 2009; 4:e7547.
14. Young SK, Ponnighaus JM, Jain S, et al. Use of short tandem repeat sequences to study Mycobacterium leprae in leprosy patients in Malawi and India. PLoS Negl Trop Dis 2008; 2:e214.
15. Monot M, Honore N, Baliere C, et al. Are variable-number tandem repeats appropriate for genotyping Mycobacterium leprae? J Clin Microbiol 2008; 46:2291-2297.
16. Varkevisser CM, Lever P, Alubo O, et al. Gender and leprosy: case studies in Indonesia, Nigeria, Nepal and Brazil. Lepr Rev 2009; 80:65-76.
17. Smith C, Richardus JH. Leprosy strategy is about control, not eradication. Lancet 2008; 371:969-970.
18. JobCK, Jayakumar J, Kearney M, et al. Transmission of leprosy: a study of skin and nasal secretions of household contacts of leprosy patients using PCR. Am J Trop Med Hyg 2008; 78:518-521.
19. Lane JE, Walsh DS, Meyers WM, etal. Borderline tuberculoid leprosy in a woman from the state of Georgia with armadillo exposure. J Am Acad Dermatol 2006; 55:714-716.
20. Clark BM, Murray CK, Horvath LL, et al. Case-control study of armadillo contact and Hansen's disease. Am J Trop Med Hyg 2008; 78:962-967.
21. Deps PD, Alves BL, Gripp CG, et al. Contact with armadillos increases the risk of leprosy in Brazil: a case control study. Indian J Dermatol Venereol Leprol 2008; 74:338-342.
22. Cardona-Castro N, Beltran JC, Ortiz-Bernal A, et al. Detection of Mycobacterium leprae DNA in nine-banded armadillos (Dasypus novemcinctus) from the Andean region of Colombia. Lepr Rev 2009; 80:424-431.
23. LoughryWJ, Truman RW, McDonoughCM, etal. Is leprosy spreading among nine-banded armadillos in the southeastern United States? J Wildl Dis 2009; 45:144-152.
24. Lavania M, Katoch K, Katoch VM, et al. Detection of viable Mycobacterium leprae in soil samples: insights into possible sources of transmission of leprosy. Infect Genet Evol 2008; 8:627-631.
25. Kar HK, Sharma P, Bhardwaj M. Borderline tuberculoid leprosy with upgrading Type 1 reaction in a HIV seropositive patient, after antiretroviral therapy: an immune reconstitution inflammatory syndrome. Lepr Rev 2009; 80:85-88.
26. Talhari C, Matsuo C, Chrusciak-Talhari A, et al. Variations in leprosy manifestations among HIV-positive patients, Manaus, Brazil. Emerg Infect Dis 2009; 15:673-674.
27. Couppie P, Domergue V, Clyti E, et al. Increased incidence of leprosy following HAART initiation: a manifestation of the immune reconstitution disease. AIDS 2009; 23:1599-1600.
28. Siddiqui MR, Velidi NR, Pati S, et al. Integration of leprosy elimination into primary healthcare in Orissa, India. PLoS One 2009; 4:e8351.
29. BurkiT. Fight against leprosy no longer about the numbers. Lancet Infect Dis 2010; 10:74.
30. World Health Organization. Global leprosy situation. Wkly Epidemiol Rec 2009; 84:333-340.
31. A day to remember leprosy. Lancet Infect Dis 2009; 9:1.
32. Alter A, De Leseleuc L, Van Thuc N, et al. Genetic and functional analysis of common MRC1 exon 7 polymorphisms in leprosy susceptibility. Hum Genet 2010; 127:337-348.
33. Zhang F, Liu H, Chen S, et al. Evidence for an association of HLA-DRB1 *15 and DRB1 *09 with leprosy and the impact of DRB1 *09 on disease onset in a Chinese Han population. BMC Med Genet 2009; 10:1 33.
34. Da Silva SA, Mazini PS, Reis PG, et al. HLA-DR and HLA-DQ alleles in patients from the south of Brazil: markers for leprosy susceptibility and resistance. BMC Infect Dis 2009; 9:134.
35. Pereira AC, Brito-de-Souza VN, Cardoso CC, etal. Genetic, epidemiological and biological analysis of interleukin-10 promoter single-nucleotide poly morphisms suggests a definitive role for-819C/T in leprosy susceptibility. Genes Immun 2009; 10:174-180.
36. Schuring RP, Hamann L, Faber WR, et al. Polymorphism N248S in the human Toll-like receptor 1 gene is related to leprosy and leprosy reactions. J Infect Dis 2009; 199:1816-1819.
37. Berrington WR, Macdonald M, Khadge S, etal. Common polymorphisms in the NOD2 gene region are associated with leprosy and its reactive states. J Infect Dis 2010; 201:1422-1435.
38. Bochud PY, Sinsimer D, Aderem A, etal. Polymorphisms in Toll-like receptor 4 (TLR4) are associated with protection against leprosy. Eur J Clin Microbiol Infect Dis 2009; 28:1055-1065.
39. Misch EA, Macdonald M, Ranjit C, et al. Human TLR1 deficiency is associated with impaired mycobacterial signaling and protection from leprosy reversal reaction. PLoS Negl Trop Dis 2008; 2:e231.
40. Bochud PY, Hawn TR, Siddiqui MR, et al. Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. J Infect Dis 2008; 197:253-261.
41. Zhang FR, Huang W, Chen SM, et al. Genomewide association study of leprosy. N Engl J Med 2009; 361:2609-2618.
42. Tobin DM, Vary JC Jr, Ray JP, et al. The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 2010; 140:717-730.
43. Scollard DM. The biology of nerve injury in leprosy. Lepr Rev 2008; 79:242-253.
44. Oliveira AL, Antunes SL, Teles RM, et al. Schwann cells producing matrix metalloproteinases under Mycobacterium leprae stimulation may play a role in the outcome of leprous neuropathy. J Neuropathol Exp Neurol 2010; 69:27-39.
45. Teles RM, Teles RB, Amadeu TP, et al. High matrix metalloproteinase production correlates with immune activation and leukocyte migration in leprosy reactional lesions. Infect Immun 2010; 78:1012-1021.
46. Modlin RL The innate immune response in leprosy. CurrOpin Immunol 2010; 22:48-54.
47. Sieling PA, Hill PJ, Dobos KM, et al. Conserved mycobacterial lipoglyco-proteins activate TLR2 but also require glycosylation for MHC class II-restricted T cell activation. J Immunol 2008; 180:5833-5842.
48. Montoya D, Cruz D, Teles RM, et al. Divergence of macrophage phagocytic and antimicrobial programs in leprosy. Cell Host Microbe 2009; 6:343-353.
49. Simoes Quaresma JA, De Oliveira MF, Ribeiro Guimaraes AC, et al. CD1a and factor XIIIa immunohistochemistry in leprosy: a possible role of dendritic cells in the pathogenesis of Mycobacterium leprae infection. Am J Derma-topathol 2009; 31:527-531.
50. Dagur PK, Sharma B, Kumar G, etal. Mycobacterial antigen(s) induce anergy by altering TCR-and TCR/CD28-induced signalling events: insights into T-cell unresponsiveness in leprosy. Mol Immunol 2010; 47:943-952.
51. Massone C, Nunzi E, Ribeiro-Rodrigues R, et al. T regulatory cells and plasmocytoid dentritic cells in Hansen disease: a new insight into pathogen esis? Am J Dermatopathol 2010; 32:251-256.
52. Zenha EM, Ferreira MA, Foss NT. Use of anti-PGL-1 antibodies to monitor therapy regimes in leprosy patients. Braz J Med Biol Res 2009; 42:968-972.
53. Sinha R, Sengupta A, Ali N, et al. Is phenolic glycolipid-I really a specific antigen for leprosy? Clin Infect Dis 2010; 50:937-938.
54. Bang PD, Suzuki K, Phuong le T, et al. Evaluation of polymerase chain reaction-based detection of Mycobacterium leprae for the diagnosis of leprosy. J Dermatol 2009; 36:269-276.
55. Lini N, Shankernarayan NP, Dharmalingam K. Quantitative real-time PCR analysis of Mycobacterium leprae DNA and mRNA in human biopsy material from leprosy and reactional cases. J Med Microbiol 2009; 58:753-759.
56. Martinez AN, Lahiri R, Pittman TL, et al. Molecular determination of Mycobacterium leprae viability by use of real-time PCR. J Clin Microbiol 2009; 47:2124-2130.
57. Stefani MM, Guerra JG, Sousa AL, etal. Potential plasma markers of Type 1 and Type 2 leprosy reactions: a preliminary report. BMC Infect Dis 2009; 9:75.
58. Gupta N, Shankernarayan NP, Dharmalingam K. Alpha-1-acid glycoprotein as a putative biomarker for monitoring the development of type II reactional stage of leprosy. J Med Microbiol 2010; 59:400-407.
59. Mendonca VA, Costa RD, Lyon S, etal. Plasma levels of chemokines during leprosy specific treatment. Acta Trop 2010; 113:151-154.
60. Leal AM, Foss NT. Endocrine dysfunction in leprosy. Eur J Clin Microbiol Infect Dis 2009; 28:1-7.
61. Villahermosa LG, Fajardo TT Jr, Abalos RM, et al. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multidrug therapy for multibacillary leprosy. Am J Trop Med Hyg 2004; 70:197-200.
62. Matsuoka M, Budiawan T, Aye KS, et al. The frequency of drug resistance mutations in Mycobacterium leprae isolates in untreated and relapsed leprosy patients from Myanmar, Indonesia and the Philippines. Lepr Rev 2007; 78:343-352.
63. Drug resistance in leprosy: reports from selected endemic countries. Wkly Epidemiol Rec 2009; 84:264-267.
64. Fajardo TT, Villahermosa L, Pardillo FE, et al. A comparative clinical trial in multibacillary leprosy with long-term relapse rates of four different multidrug regimens. Am J Trop Med Hyg 2009; 81:330-334.
65. Rao PN, Suneetha S, Pratap DV. Comparative study of uniform-MDT and WHO MDT in pauci-and multibacillary leprosy patients over 24 months of observation. Lepr Rev 2009; 80:143-155.
66. Pardillo FE, Burgos J, Fajardo TT, et al. Rapid killing of M. leprae by moxifloxacin in two patients with lepromatous leprosy. Lepr Rev 2009; 80: 205-209.
67. Desikan KV, Sundaresh P, Tulasidas I, etal. An 8-12 year follow-up of highly bacillated Indian leprosy patients treated with WHO multidrug therapy. Lepr Rev 2008; 79:303-310.
68. Balagon M, Cellona RV, dela Cruz EC, et al. Long term risk of relapse of multibacillary leprosy after completion of 2-year multiple drug therapy (WHO-MDT) in Cebu, Philippines. Am J Trop Med Hyg 2009; 81:895-899.
69. Jing Z, Zhang R, Zhou D, et al. Twenty five years follow-up of MB leprosy patients retreated with a modified MDT regimen after a full course of dapsone mono-therapy. Lepr Rev 2009; 80:170-176.
70. Gupta UD, Katoch K, Singh HB, et al. Persister studies in leprosy patients after multidrug treatment. Int J Lepr Other Mycobact Dis 2005; 73:100-104.
71. Walker SL, Lockwood DN. Leprosy type 1 (reversal) reactions and their management. Lepr Rev 2008; 79:372-386.
72. Van Veen NH, Lockwood D, Van Brakel WH, etal. Interventions for erythema nodosum leprosum. Cochrane Database Syst Rev 2009:CD006949.
73. Kaur I, Dogra S, Narang T, et al. Comparative efficacy of thalidomide and prednisolone in the treatment of moderate to severe erythema nodosum leprosum: a randomized study. Australas J Dermatol 2009; 50:181-185.
74. Lee DJ, Li H, Ochoa MT, etal. Integrated pathways for neutrophil recruitment and inflammation in leprosy. J Infect Dis 2010; 201:558-569.
75. Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science 2010; 327:1345-1350.
76. Van Veen NH, McNamee P, Richardus JH, et al. Cost-effectiveness of interventions to prevent disability in leprosy: a systematic review. PLoS One 2009; 4:e4548.
77. Smith WC, Nicholls PG, Das L, etal. Predicting neuropathy and reactions in leprosy at diagnosis and before incident events-results from the INFIR cohort study. PLoS Negl Trop Dis 2009; 3:e500.
78. Moschioni C, Antunes CM, Grossi MA, et al. Risk factors for physical disability at diagnosis of 19,283 new cases of leprosy. Rev Soc Bras Med Trop 2010; 43:19-22.
79. Schuring RP, Richardus JH, Steyerberg EW, etal. Preventing nerve function impairment in leprosy: validation and updating of a prediction rule. PLoS Negl Trop Dis 2008; 2:e283.
80. Khambati FA, Shetty VP, Ghate SD, et al. Sensitivity and specificity of nerve palpation, monofilament testing and voluntary muscle testing in detecting peripheral nerve abnormality, using nerve conduction studies as gold standard: a study in 357 patients. Lepr Rev 2009; 80:34-50.
81. Cardona-Castro N, Beltran-Alzate JC, Romero-Montoya M. Clinical, bacteriological and immunological follow-up of household contacts of leprosy patients from a postelimination area-Antioquia, Colombia. Mem Inst Oswaldo Cruz 2009; 104:935-936.
82. Queiroz JW, Dias GH, Nobre ML, et al. Geographic information systems and applied spatial statistics are efficient tools to study Hansen's disease (leprosy) and to determine areas of greater risk of disease. Am J Trop Med Hyg 2010; 82:306-314.
83. Duthie MS, Hay MN, Morales CZ, et al. Rational design and evaluation of a multiepitope chimeric fusion protein with the potential for leprosy diagnosis. Clin Vaccine Immunol 2010; 17:298-303.
84. Geluk A, Spencer JS, Bobosha K, et al. From genome-based in silico predictions to ex vivo verification of leprosy diagnosis. Clin Vaccine Immunol 2009; 16:352-359.
85. Geluk A, Van Der Ploeg-van Schip JJ, Van Meijgaarden KE, et al. Enhancing sensitivity of detection of immune responses to Mycobacterium leprae peptides in whole blood assays. Clin Vaccine Immunol 2010 [Epub ahead of print].
86. Moet FJ, Pahan D, Oskam L, et al. Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial. Br Med J 2008; 336:761-764.
87. Senior K. Stigma, chemoprophylaxis, and leprosy control. Lancet Infect Dis 2009; 9:10.
88. Schuring RP, Richardus JH, Pahan D, et al. Protective effect of the combination BCG vaccination and rifampicin prophylaxis in leprosy prevention. Vaccine 2009; 27:7125-7128.
89. Duppre NC, Camacho LA, da Cunha SS, et al. Effectiveness of BCG vaccination among leprosy contacts: a cohort study. Trans R Soc Trop Med Hyg 2008; 102:631-638.
90. Merle CS, Cunha SS, Rodrigues LC. BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control. Expert Rev Vaccines 2010; 9:209-222.
91. Setia MS, Steinmaus C, Ho CS, et al. The role of BCG in prevention of leprosy: a meta-analysis. Lancet Infect Dis 2006; 6:162-170.
92. + T lymphocytes by recombinant bacillus Calmette-Guerin that secretes heat shock protein 70-major membrane protein-II fusion protein. J Immunol 2009; 183:6561-6568.
93. Romano M, Huygen K. DNA vaccines against mycobacterial diseases. Expert Rev Vaccines 2009; 8:1237-1250.
94. Portaels F, Silva MT, Meyers WM. Buruli ulcer. Clin Dermatol 2009; 27:291-305.
95. Silva MT, Portaels F, PedrosaJ. Pathogenetic mechanisms of the intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer. Lancet Infect Dis 2009; 9:699-710.
96. Senior K. Buruli ulcer: dare we continue to ignore it? Lancet Infect Dis 2009; 9:273.
97. Buruli ulcer progress report, 2004-2008. Wkly Epidemiol Rec 2008; 83:145-154.
98. Porten K, Sailor K, Comte E, et al. Prevalence of Buruli ulcer in Akonolinga health district, Cameroon: results of a cross sectional survey. PLoS Negl Trop Dis 2009; 3:e466.
99. Walsh DS, Eyase F, Onyango D, et al. Short report: Clinical and molecular evidence for a case of Buruli ulcer (Mycobacterium ulcerans infection) in Kenya. Am J Trop Med Hyg 2009; 81:1110-1113.
100. Barogui Y, Johnson RC, Van Der Werf TS, et al. Functional limitations after surgical or antibiotic treatment for Buruli ulcer in Benin. Am J Trop Med Hyg 2009; 81:82-87.
101. McGann H,Stragier P, Portaels F, etal. Buruli ulcer in United Kingdom tourist returning from Latin America. Emerg Infect Dis 2009; 15:1827-1829.
102. Johnson PD, Lavender CJ. Correlation between Buruli ulcer and vector-borne notifiable diseases, Victoria, Australia. Emerg Infect Dis 2009; 15:614-615.
103. DurnezL, SuykerbuykP, Nicolas V, etal. The role of terrestrial small mammals as reservoir of Mycobacterium ulcerans in Benin. Appl Environ Microbiol [Epub ahead of print].
104. Jacobsen KH, Padgett JJ. Risk factors for Mycobacterium ulcerans infection. Int J Infect Dis 2010 [Epub ahead of print].
105. Johnson RC, Nackers F, Glynn JR, et al. Association of HIV infection and Mycobacterium ulcerans disease in Benin. AIDS 2008; 22:901-903.
106. Portaels F, Aguiar J, Debacker M, et al. Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect Immun 2004; 72:62-65.
107. Huygen K, Adjei O, Affolabi D, et al. Buruli ulcer disease: prospects for a vaccine. Med Microbiol Immunol 2009; 198:69-77.
108. Vandelannoote K, Durnez L, Amissah D, et al. Application of real-time PCR in Ghana, a Buruli ulcer-endemic country, confirms the presence of Mycobac terium ulcerans in the environment. FEMS Microbiol Lett 2010; 304:191-194.
109. Durnez L, Stragier P, Roebben K, et al. A comparison of DNA extraction procedures for the detection of Mycobacterium ulcerans, the causative agent of Buruli ulcer, in clinical and environmental specimens. J Microbiol Methods 2008; 76:152-158.
110. Portaels F, Meyers WM, Ablordey A, et al. First cultivation and characterization of Mycobacterium ulcerans from the environment. PLoS Negl Trop Dis 2008; 2:e178.
111. Tobias NJ, Seemann T, Pidot SJ, et al. Mycolactone gene expression is controlled by strong SigA-like promoters with utility in studies of Mycobacterium ulcerans and Buruli ulcer. PLoS Negl Trop Dis 2009; 3:e553.
112. Demangel C, StinearTP, Cole ST. Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans. Nat Rev Microbiol 2009; 7:50-60.
113. Portaels F, Fonteyne PA, De Beenhouwer H, et al. Variability in 3' end of 16S rRNA sequence of Mycobacterium ulcerans is related to geographic origin of isolates. J Clin Microbiol 1996; 34:962-965.
114. Stragier P, Ablordey A, Bayonne LM, et al. Heterogeneity among Mycobacterium ulcerans isolates from Africa. Emerg Infect Dis 2006; 12:844-847.
115. Ortiz RH, Leon DA, Estevez HO, et al. Differences in virulence and immune response induced in a murine model by isolates of Mycobacterium ulcerans from different geographic areas. Clin Exp Immunol 2009; 157:271-281.
116. Kaser M, Gutmann O, Hauser J, et al. Lack of insertional-deletional polymorphism in a collection of Mycobacterium ulcerans isolates from Ghanaian Buruli ulcer patients. J Clin Microbiol 2009; 47:3640-3646.
117. Kaser M, Hauser J, PluschkeG. Single nucleotide polymorphisms on the road to strain differentiation in Mycobacterium ulcerans. J Clin Microbiol 2009; 47:3647-3652.
118. Qi W, Kaser M, Roltgen K, et al. Genomic diversity and evolution of Mycobacterium ulcerans revealed by next-generation sequencing. PLoS Pathog 2009; 5:e1000580.
119. Boulkroun S, Guenin-Mace L, Thoulouze MI, etal. Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events. J Immunol 2010; 184:1436-1444.
120. Torrado E, Fraga AG, Logarinho E, et al. IFN-gamma-dependent activation of macrophages during experimental infections by Mycobacterium ulcerans is impaired by the toxin mycolactone. J Immunol 2010; 184:947-955.
121. Simmonds RE, Lali FV, Smallie T, et al. Mycolactone inhibits monocyte cytokine production by a posttranscriptional mechanism. J Immunol 2009; 182:2194-2202.
122. Hong H, Coutanceau E, Leclerc M, et al. Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs. PLoS Negl Trop Dis 2008; 2:e325.
123. Phillips R, Sarfo FS, Guenin-Mace L, etal. Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with Buruli ulcer disease. J Infect Dis 2009; 200:1675-1684.
124. Kiszewski AE, Becerril E, Aguilar LD, et al. The local immune response in ulcerative lesions of Buruli disease. Clin Exp Immunol 2006; 143:445-451.
125. Schutte D, Pluschke G. Immunosuppression and treatment-associated inflammatory response in patients with Mycobacterium ulcerans infection (Buruli ulcer). Expert Opin Biol Ther 2009; 9:1 87-200.
126. Schutte D, Umboock A, Pluschke G. Phagocytosis of Mycobacterium ulcerans in the course of rifampicin and streptomycin chemotherapy in Buruliulcer lesions. Br J Dermatol 2008; 160:273-283.
127. Stanford JL, Revill WD, Gunthorpe WJ, etal. The production and preliminary investigation of Burulin, a new skin test reagent for Mycobacterium ulcerans infection. J Hyg (Lond) 1975; 74:7-16.
128. Beissner M, Herbinger KH, Bretzel G. Laboratory diagnosis of Buruli ulcer disease. Future Microbiol 2010; 5:363-370.
129. Herbinger KH, Adjei O, Awua-Boateng NY, et al. Comparative study of the sensitivity of different diagnostic methods for the laboratory diagnosis of Buruli ulcer disease. Clin Infect Dis 2009; 48:1055-1064.
130. Phillips RO, Sarfo FS, Osei-Sarpong F, et al. Sensitivity of PCR targeting Mycobacterium ulcerans by use of fine-needle aspirates for diagnosis of Buruli ulcer. J Clin Microbiol 2009; 47:924-926.
131. Eddyani M, Fraga AG, Schmitt F, et al. Fine-needle aspiration, an efficient sampling technique for bacteriological diagnosis of nonulcerative Buruli ulcer. J Clin Microbiol 2009; 47:1700-1704.
132. Cassisa V, Chauty A, Marion E, et al. Use of fine needle aspiration for the diagnosis of M. ulcerans infection. J Clin Microbiol 2010 [Epub ahead of print].
133. Stragier P, Ablordey A, Durnez L, et al. VNTR analysis differentiates Mycobacterium ulcerans and IS2404 positive mycobacteria. Syst Appl Microbiol 2007; 30:525-530.
134. Sarfo FS, Phillips RO, Rangers B, et al. Detection of mycolactone A/B in Mycobacterium ulcerans-infected human tissue. PLoS Negl Trop Dis 2010; 4:e577.
135. O'Brien DP, Hughes AJ, Cheng AC, et al. Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med J Aust 2007; 186:58-61.
136. Herbinger KH, Brieske D, Nitschke J, etal. Excision of preulcerative forms of Buruli ulcer disease: a curative treatment? Infection 2009; 37:20-25.
137. Schunk M, Thompson W, Klutse E, et al. Outcome of patients with buruli ulcer after surgical treatment with or without antimycobacterial treatment in Ghana. Am J Trop Med Hyg 2009; 81:75-81.
138. Etuaful S, Carbonnelle B, Grosset J, et al. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 2005; 49:3182-3186.
139. WHO/CDS/CPE/GBUI/2004. Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer). Geneva: World Health Organization; 2004.
140. Chauty A, Ardant MF, Adeye A, et al. Promising clinical efficacy of strepto-mycin-rifampin combination for treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 2007; 51:4029-4035.
141. Nienhuis WA, Stienstra Y, Thompson WA, et al. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 2010; 375:664-672.
142. Johnson PD. Should antibiotics be given for Buruli ulcer? Lancet 2010; 375:618-619.
143. Dossou AD, Sopoh GE, Johnson CR, et al. Management of Mycobacterium ulcerans infection in a pregnant woman in Benin using rifampicin and clarithromycin. Med J Aust 2008; 189:532-533.
144. Ji B, Chauffour A, Robert J, et al. Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother 2008; 52:1912-1916.
145. Kibadi K, Boelaert M, Fraga AG, etal. Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli ulcer (Mycobacterium ulcerans disease). PLoS Negl Trop Dis (in press).
146. Junghanss T, Um Boock A, Vogel M, et al. Phase change material for thermotherapy of Buruli ulcer: a prospective observational single centre proof-of-principle trial. PLoS Negl Trop Dis 2009; 3:e380.
147. O'Brien DP, Robson ME, Callan PP, et al. "Paradoxical" immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. Med J Aust 2009; 191:564-566.